Dr. Cerilli primarily studies two critical areas: traumatic injuries to the thoracic aorta, a major blood vessel that can suffer life-threatening ruptures, and kidney transplantation. In his work on thoracic aortic injuries, he examines how patients fare after experiencing such serious trauma, as these injuries can often be fatal. He also researches the role of donor-specific antibodies in kidney transplants, which can help determine the likelihood of a successful recovery for patients. His findings guide medical professionals in treating patients more effectively, thus increasing survival rates and reducing complications.
Key findings
In a study on thoracic aortic injury, 23% of the patients died before treatment, but stable patients had no deaths despite an average surgery delay of 21 days.
For kidney transplant patients without specific antibodies, 95% experienced a smooth recovery, whereas those with antibodies faced an 80% chance of serious rejection issues.
These results emphasize the importance of assessing patient stability and antibody presence to enhance surgical outcomes and post-transplant care.
Frequently asked questions
Does Dr. Cerilli study thoracic aortic injuries?
Yes, he studies outcomes related to traumatic ruptures of the thoracic aorta and their management.
What treatments has Dr. Cerilli researched?
He has researched surgical interventions for thoracic aortic injuries and kidney transplantation techniques.
Is Dr. Cerilli's work relevant to kidney transplant patients?
Absolutely, his research on donor-specific antibodies is crucial for identifying kidney transplant patients at risk of complications.
Publications in plain English
Outcome after thoracic aortic injury: experience in a level-1 trauma center.
2008
Annals of vascular surgery
Duwayri Y, Abbas J, Cerilli G, Chan E, Nazzal M
Plain English This study looked at the outcomes of patients who suffered a serious injury called a traumatic rupture of the thoracic aorta, which is often fatal. Out of 30 patients, 23% died before receiving treatment, and 47% were unstable when they arrived at the hospital. In contrast, patients who were stable had no deaths, even when repairs were delayed for an average of nearly 21 days.
Who this helps: This research assists doctors and healthcare teams in managing patients with thoracic aortic injuries, improving survival rates by understanding when surgery can be safely delayed.
The significance of a donor-specific vessel crossmatch in renal transplantation.
1988
Transplantation
Cerilli J, Clarke J, Doolin T, Cerilli G, Brasile L
Plain English This study looked at how specific antibodies related to blood vessel cells (VEC) in transplant donors might affect kidney transplant success. Researchers found that when patients don't have these antibodies before surgery, 95% of them enjoy a smooth recovery. However, if the antibodies are present, there's an 80% chance of serious rejection problems post-transplant. This means that testing for these antibodies could help identify patients at higher risk for transplant failure.
Who this helps: Patients receiving kidney transplants.